Ocular Therapeutix
OCUL
186 hedge funds and large institutions have $1.45B invested in Ocular Therapeutix in 2025 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 75 increasing their positions, 48 reducing their positions, and 31 closing their positions.
137% more call options, than puts
Call options by funds: $9.7M | Put options by funds: $4.1M
56% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 48
44% more capital invested
Capital invested by funds: $1.01B → $1.45B (+$447M)
12.21% more ownership
Funds ownership: 86.38% → 98.59% (+12%)
0% more funds holding in top 10
Funds holding in top 10: 10 → 10 (0)
5% less funds holding
Funds holding: 196 → 186 (-10)
23% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$146M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$16.5M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$10.6M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$5.75M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$4.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$11.5M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$10.3M |
| 3 |
PA
Perceptive Advisors
New York
|
-$6.71M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$5.17M |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$4.04M |
OCUL Hedge Fund Activity: Q2 2025 in Review
186 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q2 2025, worth a combined $1.45B — up 44% from $1.01B a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of OCUL and 24 opened new positions — a net loss of 7 holders — while 48 trimmed existing stakes and 75 added.
The largest buyer was Fidelity Investments, adding an estimated $146M. The largest seller was BlackRock, cutting an estimated $11.5M.
- 186 institutional investors held Ocular Therapeutix (OCUL) as of Q2 2025, down from 196 in Q1 2025.
- Funds reported $1.45B of Ocular Therapeutix stock for Q2 2025, up 44% quarter-over-quarter.
- 24 funds opened new Ocular Therapeutix positions in Q2 2025 and 31 closed out, a net change of -7 holders.
- The largest Ocular Therapeutix buyer in Q2 2025 was Fidelity Investments, an estimated $146M added.
- The largest Ocular Therapeutix seller in Q2 2025 was BlackRock, an estimated $11.5M sold.
Based on aggregated 13F filings for Q2 2025.